Daiichi Sankyo appoints Hiroyuki Okuzawa as chief executive officer: Tokyo Saturday, February 1, 2025, 12:30 Hrs [IST] ...
Q3 2024 Management View Revenue for Q3 FY2024 increased 16.6% year-on-year to ¥1,367.6 billion, driven by growth in oncology ...
Basel: Roche has announced that the U.S. Food and Drug Administration (FDA) has approved a label expansion for the PATHWAY ...
GlobalData on MSN22h
Hiroyuki Okuzawa succeeds Sunao Manabe as Daiichi Sankyo CEODaiichi Sankyo has announced that Hiroyuki Okuzawa will succeed Sunao Manabe as its CEO from 1 April 2025. The company's ...
Several medicines are poised to reach new heights after winning key endorsements from European drug regulators. | Among those ...
Roche’s PATHWAY HER2 (4B5) test helps identify patients with HER2-ultralow breast cancer, who may be eligible for targeted ...
As seen in the DESTINY-Breast06 trial, a pproximately 20-25 percent of hormone receptor (HR)-positive, HER2- ...
Daiichi Sankyo promoted Hiroyuki Okuzawa to CEO, and he will take over from Sunao Manabe on April 1. Okuzawa is currently Daiichi’s chief operating officer.
AstraZeneca (AZN) stock in focus as its partner Daiichi Sankyo (DSNKY) wins EU backing for their jointly developed breast ...
The firms will evaluate two adjuvant treatment options, Datroway with rilvegostomig or rilvegostomig monotherapy, against standard-of-care treatment.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback